Results 121 to 130 of about 13,011 (272)

Deferasirox in mucormycosis: hopefully, not defeated [PDF]

, 2011
R. Soman, Neha Gupta, Anjali Shetty, Camilla Rodrigues   +3 more
openalex   +1 more source

Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.

PLoS ONE, 2018
Chronic blood transfusions are responsible to cause iron overload, which leads to several complications to end organs and osteoporosis. Iron chelation is needed to remove iron excess and to contain bone-mass loss. Deferasirox is the most recent oral iron
Francesca Punzo, Chiara Tortora, Maura Argenziano, Maddalena Casale, Silverio Perrotta, Francesca Rossi   +5 more
doaj   +1 more source

R2 imaging of ferritin iron in thalassaemia patients off and on iron-chelation therapy [PDF]

, 2009
Myocardial Tissue Characterization: Fat, Hemorrhage & Edema - Poster presentationAccurate assessment of iron burden is crucial for the management of iron-chelation therapy.
Brittenham, GM, Brown, TR, Jensen, JH, Kim, D, Sheth, SS, Tosti, CL, Wu, EX   +6 more
core  

A synopsis of current care of thalassaemia major patients in Hong Kong [PDF]

, 2011
OBJECTIVE: To provide a synopsis of current thalassaemia major patient care in Hong Kong. DESIGN: Retrospective study. SETTING: All haematology units of the Hospital Authority in Hong Kong.
Au, WY, Chan, D, Chan, EYT, Cheung, WWW, Ha, SY, Kho, B, Lau, CW, Lee, CY, Lee, V, Li, CK, Li, RCH, Lin, SY, Ling, ASC, Mak, V, Sun, L, Wong, KHF, Wong, R, Yau, J, Yuen, HL   +18 more
core  

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions

Therapeutics and Clinical Risk Management, 2016
Anna W Chalmers, Jamile M Shammo Department of Internal Medicine, Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA Abstract: Transfusion-dependent anemia is a common feature in a wide array of hematological disorders ...
Chalmers AW, Shammo JM
doaj  

Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan [PDF]

, 2018
Bor‐Sheng Ko, Ming-Chih Chang, Tzeon-Jye Chiou, Te-Kau Chang, Yeu-Chin Chen, Sheng-Fung Lin, Cheng-Shyong Chang, Yin-Che Lu, Su-Peng Yeh, Tsai‐Yun Chen, Wei-Shou Hwang   +10 more
openalex   +1 more source

Iron overload as a consequence of red blood cell transfusions in patients with hematological diseases [PDF]

, 2010
Preopterećenje željezom česta je i ozbiljna komplikacija višestrukih transfuzija deplazmatiziranih eritrocita koja pridonosi oštećenju organa te utječe na preživljenje bolesnika s hematološkim bolestima.
Antica Načinović-Duletić, Duška Petranović, Ivan Host, Toni Valković   +3 more
core   +3 more sources

In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics

, 2021
Axel Steinbrueck, Adam C. Sedgwick, Hai‐Hao Han, Michael Y. Zhao, Sajal Sen, Dan‐Ying Huang, Yi Zang, Jia Li, Xiao‐Peng He, Jonathan L. Sessler   +9 more
openalex   +2 more sources

Hubungan Derajat Klinis dengan Kadar Feritin Penyandang Thalassemia Β di RSUD Arifin Achmad [PDF]

, 2016
Thalassemia is a genetic disorder which there is interference with the synthesis of hemoglobin that causes a decreased of synthesis of α or β chain, If the abnormalities are β chain called β thalassemia.
Ridar, E. (Elmi), Satria, A. (Adriyan), Tampubolon, L. (Lucyana)   +2 more
core  

Early Kidney Damage Markers after Deferasirox Treatment in Patients with Thalassemia Major: A Case-Control Study [PDF]

, 2019
Hamidreza Badeli, Adel Baghersalimi, Sajjad Eslami, Farshid Saadat, Afagh Hassanzadeh Rad, Rokhsar Basavand, Soghra Rafiei Papkiadeh, Bahram Darbandi, Wesam Kooti, Ilaria Peluso   +9 more
openalex   +1 more source